Study objectives and endpoints
death, Tumor
SOLID TUMOR, TUMOR
The main objective of this study is to identify effective biomarkers of response to PD-1 checkpoint blockade using combinatorial omics analysis including spatial transcriptomics, scRNA-seq, and miRNomics. The primary endpoint is the prospective validation of the IFN-γ–related gene expression signature to predict response to PD-1 checkpoint blockade (overall response including complete response (CR) and partial response (PR)). Tumor response was defined according to the Response Evaluation Criteria In Solid Tumor (RECIST) criteria. Secondary outcomes are the prospective validation of potential response biomarkers (immunogenic cell death and mitophagy-related markers, expression of hypoxia-related markers, and circulating miRNA-mediated immunomodulation). Exploratory outcome measures will include dynamic and differential profiling of the immune repertoire in the TME between responders and non-responders.